Although major adverse events have not been reported in any clinical trial performed in India, careful attention should be paid to whether saroglitazar improves NASH or not and to what extent the adverse events are compared with those observed with other (abandoned) PPARα/γ dual agonists. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.